董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Balkrishan Gill | 男 | Director | 61 | 未披露 | 22.68 | 2026-02-23 |
| Michael Mendelsohn | 男 | Director | 70 | 14.73万美元 | 18.01 | 2026-02-23 |
| Adrian Gottschalk | 男 | Director and Chief Executive Officer | 51 | 236.10万美元 | 275.34 | 2026-02-23 |
| Neil Gallagher | 男 | Director | 62 | 19.30万美元 | 1.67 | 2026-02-23 |
| Stuart Duty | 男 | Director | 61 | 19.47万美元 | 1.67 | 2026-02-23 |
| Thomas J. Lynch | 男 | Director | -- | 14.01万美元 | 8.90 | 2026-02-23 |
| Ian Smith | 男 | Director | 60 | 13.20万美元 | 23.40 | 2026-02-23 |
| B. Lynne Parshall | 女 | Director | 71 | 15.18万美元 | 8.90 | 2026-02-23 |
| Scott Biller | 男 | Director | 70 | 13.68万美元 | 18.01 | 2026-02-23 |
| Douglas G. Cole | 男 | Director | 65 | 17.73万美元 | 8.55 | 2026-02-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adrian Gottschalk | 男 | Director and Chief Executive Officer | 51 | 236.10万美元 | 275.34 | 2026-02-23 |
| Steven F. Bellon | 男 | Chief Scientific Officer | 61 | 119.95万美元 | 63.71 | 2026-02-23 |
| Michael LaCascia | 男 | Chief Legal Officer | 61 | 198.88万美元 | 未持股 | 2026-02-23 |
| Carlos Costa | 男 | Chief People Officer | 53 | 未披露 | 未持股 | 2026-02-23 |
| Alfonso Quintás Cardama | 男 | Chief Medical Officer | 55 | 113.40万美元 | 25.92 | 2026-02-23 |
| Anna Rivkin | 女 | Chief Business Officer | 52 | 147.26万美元 | 未持股 | 2026-02-23 |
| Ryan D. Maynard | 男 | Chief Financial Officer and Principal Accounting Officer | 56 | 未披露 | 未持股 | 2026-02-23 |
董事简历
中英对照 | 中文 | 英文- Balkrishan Gill
-
Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD. - Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
- Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD.
- Michael Mendelsohn
-
Michael Mendelsohn自2017年4月以来一直担任我们的董事会成员。Mendelsohn博士也是Cyclerion Pharmaceuticals的董事会成员，他自2019年4月起在该公司任职，并自2016年5月起担任Cardurion Pharmaceuticals的执行主席兼总裁。自2015年4月以来，Mendelsohn博士还一直担任Takeda Pharmaceutical Co.Ltd.首席医疗和科学官的高级顾问和顾问。2014年12月至2018年12月，他担任Ironwood Pharmaceuticals首席科学官兼研究与开发总裁的高级顾问和顾问，以及制药咨询委员会成员。2014年5月至2017年7月，Mendelsohn博士是SV Health Investors的风险合伙人。在此之前，Mendelsohn博士于2010年6月至2013年11月担任默克研究实验室的高级副总裁兼心血管研究全球主管。从1993年到2010年，他曾担任Tufts Medical Center和Tufts University School of Medicine的教员，在那里他曾创立分子心脏病研究所（the Molecular Cardiology Research Institute），并担任执行董事（从1997年到2010年），也曾担任首席科学官（从2008年到2010年）。Mendelsohn博士之前是Brigham and Women&8217；s Hospital和Harvard Medical School心血管学院的成员。Mendelsohn博士在阿默斯特学院（Amherst College）获得学士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位。
Michael Mendelsohn,is also the Founder and Board Chairman, as well as the Chief Strategy Officer, of Cardurion Pharmaceuticals, where he has served since May 2016. Since November 2022, Dr. Mendelsohn has served as a member of the board of Broadview Ventures. From December 2014 to December 2018, Dr. Mendelsohn served at Ironwood Pharmaceuticals as a member of the pharmaceuticals advisory committee for the chief scientific officer and president of R&D. From May 2014 to July 2017, Dr. Mendelsohn was a venture partner for SV Health Investors. From June 2010 to November 2013, Dr. Mendelsohn served as Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories. From 1993 to 2010, Dr. Mendelsohn was a Professor of Medicine and Cardiology at Tufts Medical Center and Tufts University School of Medicine, where he founded and was the executive director of the Molecular Cardiology Research Institute from 1997 to 2010. From 2008 to 2010, he also served as Chief Scientific Officer at Tufts. From 1987 to 1993, Dr. Mendelsohn was a member of the faculty of the Cardiovascular Division at Brigham and Women's Hospital and Harvard Medical School. Dr. Mendelsohn received a B.A. in Chemistry and English from Amherst College and an M.D. from Harvard Medical School. - Michael Mendelsohn自2017年4月以来一直担任我们的董事会成员。Mendelsohn博士也是Cyclerion Pharmaceuticals的董事会成员，他自2019年4月起在该公司任职，并自2016年5月起担任Cardurion Pharmaceuticals的执行主席兼总裁。自2015年4月以来，Mendelsohn博士还一直担任Takeda Pharmaceutical Co.Ltd.首席医疗和科学官的高级顾问和顾问。2014年12月至2018年12月，他担任Ironwood Pharmaceuticals首席科学官兼研究与开发总裁的高级顾问和顾问，以及制药咨询委员会成员。2014年5月至2017年7月，Mendelsohn博士是SV Health Investors的风险合伙人。在此之前，Mendelsohn博士于2010年6月至2013年11月担任默克研究实验室的高级副总裁兼心血管研究全球主管。从1993年到2010年，他曾担任Tufts Medical Center和Tufts University School of Medicine的教员，在那里他曾创立分子心脏病研究所（the Molecular Cardiology Research Institute），并担任执行董事（从1997年到2010年），也曾担任首席科学官（从2008年到2010年）。Mendelsohn博士之前是Brigham and Women&8217；s Hospital和Harvard Medical School心血管学院的成员。Mendelsohn博士在阿默斯特学院（Amherst College）获得学士学位，在哈佛医学院（Harvard Medical School）获得医学博士学位。
- Michael Mendelsohn,is also the Founder and Board Chairman, as well as the Chief Strategy Officer, of Cardurion Pharmaceuticals, where he has served since May 2016. Since November 2022, Dr. Mendelsohn has served as a member of the board of Broadview Ventures. From December 2014 to December 2018, Dr. Mendelsohn served at Ironwood Pharmaceuticals as a member of the pharmaceuticals advisory committee for the chief scientific officer and president of R&D. From May 2014 to July 2017, Dr. Mendelsohn was a venture partner for SV Health Investors. From June 2010 to November 2013, Dr. Mendelsohn served as Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories. From 1993 to 2010, Dr. Mendelsohn was a Professor of Medicine and Cardiology at Tufts Medical Center and Tufts University School of Medicine, where he founded and was the executive director of the Molecular Cardiology Research Institute from 1997 to 2010. From 2008 to 2010, he also served as Chief Scientific Officer at Tufts. From 1987 to 1993, Dr. Mendelsohn was a member of the faculty of the Cardiovascular Division at Brigham and Women's Hospital and Harvard Medical School. Dr. Mendelsohn received a B.A. in Chemistry and English from Amherst College and an M.D. from Harvard Medical School.
- Adrian Gottschalk
-
Adrian Gottschalk自2017年5月起担任我们的总裁，首席执行官和董事会成员。在加入Foghorn之前，Gottschalk先生自2004年起在BiogenInc.工作，最近于2015年11月至2017年5月担任高级副总裁和神经变性治疗区负责人。在这个职位上，他负责阿尔茨海默氏症，帕金森氏症和肌萎缩侧索硬化症（ALS）药物的后期开发和商业化。Gottschalk先生拥有德州农工大学（Texas A&M University）的B.S.学位，麻省理工学院斯隆管理学院（Sloan School of Management at the Massachusetts Institute of Technology）的工商管理硕士学位和哈佛医学院/麻省理工学院联合健康科学与技术部门HST生物医学企业计划的硕士学位。
Adrian Gottschalk,worked at Biogen Inc. where he was most recently a Senior Vice President and Neurodegeneration Therapeutic Area Head from November 2015 to May 2017. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, or ALS. Mr. Gottschalk holds a B.S. from Texas A&M University, an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and an M.S. from the joint Harvard Medical School / Massachusetts Institute of Technology Division of Health Sciences & Technology (HST) Biomedical Enterprise Program. - Adrian Gottschalk自2017年5月起担任我们的总裁，首席执行官和董事会成员。在加入Foghorn之前，Gottschalk先生自2004年起在BiogenInc.工作，最近于2015年11月至2017年5月担任高级副总裁和神经变性治疗区负责人。在这个职位上，他负责阿尔茨海默氏症，帕金森氏症和肌萎缩侧索硬化症（ALS）药物的后期开发和商业化。Gottschalk先生拥有德州农工大学（Texas A&M University）的B.S.学位，麻省理工学院斯隆管理学院（Sloan School of Management at the Massachusetts Institute of Technology）的工商管理硕士学位和哈佛医学院/麻省理工学院联合健康科学与技术部门HST生物医学企业计划的硕士学位。
- Adrian Gottschalk,worked at Biogen Inc. where he was most recently a Senior Vice President and Neurodegeneration Therapeutic Area Head from November 2015 to May 2017. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, or ALS. Mr. Gottschalk holds a B.S. from Texas A&M University, an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and an M.S. from the joint Harvard Medical School / Massachusetts Institute of Technology Division of Health Sciences & Technology (HST) Biomedical Enterprise Program.
- Neil Gallagher
-
Neil Gallagher，自2024年4月起担任Zymeworks Inc.董事会成员。Gallagher博士自2023年4月起担任Syndax Pharmaceuticals, Inc.总裁兼研发主管。2020年1月至2023年4月，他在艾伯维公司担任首席医疗官、副总裁、开发主管。2017年11月至2019年12月，Gallagher博士在艾伯维担任全球肿瘤学开发主管。在加入艾伯维之前，他于2016年5月至2017年10月在安进担任肿瘤和炎症开发主管，并在诺华肿瘤学工作了十年。在其职业生涯的早期，他曾担任阿斯利康的医学科学总监，后来担任Astex Therapeutics的临床开发总监。Gallagher博士在英国伯明翰大学癌症研究所完成了妇科肿瘤学研究金，并在都柏林三一学院获得医学学位。
Neil Gallagher,has served as a member of Zymeworks Inc. Board of Directors since April 2024. Dr. Gallagher has served as the President, Head of Research & Development at Syndax Pharmaceuticals, Inc., since April 2023. From January 2020 to April 2023, he served as the Chief Medical Officer, Vice President, Head of Development at AbbVie Inc. From November 2017 to December 2019, Dr. Gallagher served as the Head of Global Oncology Development at AbbVie. Prior to joining AbbVie, he served as Head of Development for Oncology and Inflammation at Amgen from May 2016 to October 2017 and spent a decade at Novartis Oncology. Earlier in his career, he was a Medical Science Director at AstraZeneca and later Director of Clinical Development at Astex Therapeutics. Dr. Gallagher completed his Fellowship in Gynecological Oncology at the Institute for Cancer Studies, University of Birmingham, United Kingdom and received his medical degree from Trinity College, Dublin. - Neil Gallagher，自2024年4月起担任Zymeworks Inc.董事会成员。Gallagher博士自2023年4月起担任Syndax Pharmaceuticals, Inc.总裁兼研发主管。2020年1月至2023年4月，他在艾伯维公司担任首席医疗官、副总裁、开发主管。2017年11月至2019年12月，Gallagher博士在艾伯维担任全球肿瘤学开发主管。在加入艾伯维之前，他于2016年5月至2017年10月在安进担任肿瘤和炎症开发主管，并在诺华肿瘤学工作了十年。在其职业生涯的早期，他曾担任阿斯利康的医学科学总监，后来担任Astex Therapeutics的临床开发总监。Gallagher博士在英国伯明翰大学癌症研究所完成了妇科肿瘤学研究金，并在都柏林三一学院获得医学学位。
- Neil Gallagher,has served as a member of Zymeworks Inc. Board of Directors since April 2024. Dr. Gallagher has served as the President, Head of Research & Development at Syndax Pharmaceuticals, Inc., since April 2023. From January 2020 to April 2023, he served as the Chief Medical Officer, Vice President, Head of Development at AbbVie Inc. From November 2017 to December 2019, Dr. Gallagher served as the Head of Global Oncology Development at AbbVie. Prior to joining AbbVie, he served as Head of Development for Oncology and Inflammation at Amgen from May 2016 to October 2017 and spent a decade at Novartis Oncology. Earlier in his career, he was a Medical Science Director at AstraZeneca and later Director of Clinical Development at Astex Therapeutics. Dr. Gallagher completed his Fellowship in Gynecological Oncology at the Institute for Cancer Studies, University of Birmingham, United Kingdom and received his medical degree from Trinity College, Dublin.
- Stuart Duty
-
Stuart Duty，曾于2012年6月至2023年3月在全球投资和咨询金融服务公司Guggenheim Securities，LLC担任高级董事总经理。此前，他曾于2007年至2012年在全球投资公司Piper Jaffray Companies担任董事总经理、医疗保健投资银行业务联席主管，担任专注于私人医疗保健投资基金Oracle Partners，L.P.的首席运营官，2002年至2007年在全球投资银行Piper Jaffray，Inc.担任董事总经理、医疗保健投资银行业务联席主管，1992年至2002年在投资银行Montgomery Securities担任医疗保健投资银行业务董事总经理，1993年至1999年在生物治疗公司Curative Technologies，Inc.担任业务发展总监。Duty先生自2023年10月起在Eyepoint Pharmaceuticals，Inc.（一家上市制药公司）的董事会任职，自2024年7月起在Milestone制药，Inc.的董事会任职。Duty先生拥有西方学院的生物化学学士学位和哈佛商学院的工商管理硕士学位。
Stuart Duty,was a Senior Managing Director at Guggenheim Securities, LLC, a global investment and advisory financial services firm, from June 2012 to March 2023. Previously, he served as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray Companies, a global investment firm, from 2007 to 2012, as the Chief Operating Officer of Oracle Partners, L.P., a private healthcare focused investment fund, from 2002 to 2007, as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray, Inc., a global investment bank, from 1992 to 2002, as Managing Director, Healthcare Investment Banking at Montgomery Securities, an investment bank, from 1993 to 1999 and as the Director of Business Development at Curative Technologies, Inc., a biotherapeutics company, from 1992 to 1993. Mr. Duty has served on the board of directors of Eyepoint Pharmaceuticals, Inc., a publicly traded pharmaceutical company, since October 2023, on the board of Milestone Pharmaceuticals, Inc. since July 2024 and on the board of Foghorn Therapeutics, Inc. since May 2025. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A. from Harvard Business School. - Stuart Duty，曾于2012年6月至2023年3月在全球投资和咨询金融服务公司Guggenheim Securities，LLC担任高级董事总经理。此前，他曾于2007年至2012年在全球投资公司Piper Jaffray Companies担任董事总经理、医疗保健投资银行业务联席主管，担任专注于私人医疗保健投资基金Oracle Partners，L.P.的首席运营官，2002年至2007年在全球投资银行Piper Jaffray，Inc.担任董事总经理、医疗保健投资银行业务联席主管，1992年至2002年在投资银行Montgomery Securities担任医疗保健投资银行业务董事总经理，1993年至1999年在生物治疗公司Curative Technologies，Inc.担任业务发展总监。Duty先生自2023年10月起在Eyepoint Pharmaceuticals，Inc.（一家上市制药公司）的董事会任职，自2024年7月起在Milestone制药，Inc.的董事会任职。Duty先生拥有西方学院的生物化学学士学位和哈佛商学院的工商管理硕士学位。
- Stuart Duty,was a Senior Managing Director at Guggenheim Securities, LLC, a global investment and advisory financial services firm, from June 2012 to March 2023. Previously, he served as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray Companies, a global investment firm, from 2007 to 2012, as the Chief Operating Officer of Oracle Partners, L.P., a private healthcare focused investment fund, from 2002 to 2007, as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray, Inc., a global investment bank, from 1992 to 2002, as Managing Director, Healthcare Investment Banking at Montgomery Securities, an investment bank, from 1993 to 1999 and as the Director of Business Development at Curative Technologies, Inc., a biotherapeutics company, from 1992 to 1993. Mr. Duty has served on the board of directors of Eyepoint Pharmaceuticals, Inc., a publicly traded pharmaceutical company, since October 2023, on the board of Milestone Pharmaceuticals, Inc. since July 2024 and on the board of Foghorn Therapeutics, Inc. since May 2025. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A. from Harvard Business School.
- Thomas J. Lynch
-
Thomas J. Lynch，是世界著名科学家、备受尊敬的肿瘤学家，国家癌症研究所定点综合性癌症中心的成功带头人。自2020年2月以来，林奇博士担任Fred Hutchinson癌症研究中心总裁兼主任，负责制定该中心的战略方向，监督整个中心的举措，并向主要合作伙伴和政府机构代表Hutch的利益。他还领导了Fred Hutch/华盛顿大学癌症联盟，并且是其癌症中心支持拨款的首席研究员。在接任和记第六任总裁之前，林奇博士最近一次是在2017年3月至2019年10月期间担任百时美施贵宝的首席科学官。在此之前，他曾于2015年9月至2017年3月担任马萨诸塞州全科医生组织的首席执行官，2009年4月至2015年3月担任耶鲁大学癌症中心主任和耶鲁Smilow癌症医院的主治医师。在担任这些职务之前，林奇博士是麻省总医院血液肿瘤科主任和哈佛医学院医学教授。林奇博士是美国癌症研究协会、美国临床肿瘤学会和国际肺癌研究协会的成员。在他职业生涯的早期，他是第一个研究团队的成员，该团队发现靶向疗法如何显着改变EGFR或表皮生长因子受体基因突变的肺癌患者的结果
Thomas J. Lynch,is a world-renowned scientist, highly respected oncologist and successful leader of National Cancer Institute-Designated Comprehensive Cancer Centers. Since February 2020, Dr. Lynch has served as president and director of Fred Hutchinson Cancer Research Center, where he sets the strategic direction of the center, oversees center-wide initiatives and represents the Hutch's interests to major partners and governmental bodies. He also directs the Fred Hutch/University of Washington Cancer Consortium and is principal investigator of its Cancer Center Support Grant. Before taking over as the Hutch's sixth president, Dr. Lynch was most recently chief scientific officer of Bristol-Myers Squibb from March 2017 to October 2019. Prior to that he held leadership roles as CEO of Massachusetts General Physicians Organization from September 2015 to March 2017, director of Yale Cancer Center and physician-in-chief at Yale's Smilow Cancer Hospital from April 2009 through March 2015. Prior to those positions, Dr. Lynch was chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. - Thomas J. Lynch，是世界著名科学家、备受尊敬的肿瘤学家，国家癌症研究所定点综合性癌症中心的成功带头人。自2020年2月以来，林奇博士担任Fred Hutchinson癌症研究中心总裁兼主任，负责制定该中心的战略方向，监督整个中心的举措，并向主要合作伙伴和政府机构代表Hutch的利益。他还领导了Fred Hutch/华盛顿大学癌症联盟，并且是其癌症中心支持拨款的首席研究员。在接任和记第六任总裁之前，林奇博士最近一次是在2017年3月至2019年10月期间担任百时美施贵宝的首席科学官。在此之前，他曾于2015年9月至2017年3月担任马萨诸塞州全科医生组织的首席执行官，2009年4月至2015年3月担任耶鲁大学癌症中心主任和耶鲁Smilow癌症医院的主治医师。在担任这些职务之前，林奇博士是麻省总医院血液肿瘤科主任和哈佛医学院医学教授。林奇博士是美国癌症研究协会、美国临床肿瘤学会和国际肺癌研究协会的成员。在他职业生涯的早期，他是第一个研究团队的成员，该团队发现靶向疗法如何显着改变EGFR或表皮生长因子受体基因突变的肺癌患者的结果
- Thomas J. Lynch,is a world-renowned scientist, highly respected oncologist and successful leader of National Cancer Institute-Designated Comprehensive Cancer Centers. Since February 2020, Dr. Lynch has served as president and director of Fred Hutchinson Cancer Research Center, where he sets the strategic direction of the center, oversees center-wide initiatives and represents the Hutch's interests to major partners and governmental bodies. He also directs the Fred Hutch/University of Washington Cancer Consortium and is principal investigator of its Cancer Center Support Grant. Before taking over as the Hutch's sixth president, Dr. Lynch was most recently chief scientific officer of Bristol-Myers Squibb from March 2017 to October 2019. Prior to that he held leadership roles as CEO of Massachusetts General Physicians Organization from September 2015 to March 2017, director of Yale Cancer Center and physician-in-chief at Yale's Smilow Cancer Hospital from April 2009 through March 2015. Prior to those positions, Dr. Lynch was chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.
- Ian Smith
-
Ian Smith，自2007年2月起成为董事会成员。他自2006年2月至今担任Vertex Pharmaceuticals Inc的执行副总裁兼首席财务官。2003年11月至2006年2月，他曾担任高级副总裁兼首席财务官， 并在2001年10月至2003年11月间担任Vertex的副总裁兼首席财务官。1999至2001年，他曾在安永会计师事务所担任生命科学与技术业务组的合伙人。他最初于1987年进入安永的英国办事处，随后于1995年进入波士顿办事处。他目前担任 Infinity Pharmaceuticals Inc的董事会成员。此外，在过去五年内，他曾任Predix Pharmaceuticals Inc、Epix Pharmaceuticals Inc和 TolerRx Inc的董事会成员。他在英国的曼彻斯特大学获得财会专业文学士学位，是美国会计师公会会员，且是英格兰及威尔斯特许会计师。
Ian Smith,serves as Executive Chair of the board of directors of Solid Biosciences since April 2020, Board Chair of Rivus Pharmaceuticals since November 2023, Board Chair of iVexSol Inc. since August 2023, as a board member of Alkeus Pharmaceuticals since December 2022, a board member of Stoke Therapeutics since September 2023, and board member of Odyssey Therapeutics since October 2024. Mr. Smith also provides advisory and consulting services to these companies and other biotechnology companies. Prior to his current roles, Mr. Smith was Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals from September 2017 to January 2019 and prior to that served as Chief Financial Officer from October 2001 to September 2017. Prior to 2001, Mr. Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP. Mr. Smith received a B.A. with honors in accounting and finance from Manchester Metropolitan (UK). - Ian Smith，自2007年2月起成为董事会成员。他自2006年2月至今担任Vertex Pharmaceuticals Inc的执行副总裁兼首席财务官。2003年11月至2006年2月，他曾担任高级副总裁兼首席财务官， 并在2001年10月至2003年11月间担任Vertex的副总裁兼首席财务官。1999至2001年，他曾在安永会计师事务所担任生命科学与技术业务组的合伙人。他最初于1987年进入安永的英国办事处，随后于1995年进入波士顿办事处。他目前担任 Infinity Pharmaceuticals Inc的董事会成员。此外，在过去五年内，他曾任Predix Pharmaceuticals Inc、Epix Pharmaceuticals Inc和 TolerRx Inc的董事会成员。他在英国的曼彻斯特大学获得财会专业文学士学位，是美国会计师公会会员，且是英格兰及威尔斯特许会计师。
- Ian Smith,serves as Executive Chair of the board of directors of Solid Biosciences since April 2020, Board Chair of Rivus Pharmaceuticals since November 2023, Board Chair of iVexSol Inc. since August 2023, as a board member of Alkeus Pharmaceuticals since December 2022, a board member of Stoke Therapeutics since September 2023, and board member of Odyssey Therapeutics since October 2024. Mr. Smith also provides advisory and consulting services to these companies and other biotechnology companies. Prior to his current roles, Mr. Smith was Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals from September 2017 to January 2019 and prior to that served as Chief Financial Officer from October 2001 to September 2017. Prior to 2001, Mr. Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP. Mr. Smith received a B.A. with honors in accounting and finance from Manchester Metropolitan (UK).
- B. Lynne Parshall
-
B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University. - B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
- B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University.
- Scott Biller
-
Scott Biller于2010年9月加入Agios担任首席科学官，拥有超过25年的药物开发经验。最近，从2003年到2010年9月比勒博士是Novartis研究所的副总裁。在此之前，担任副总裁的位置。他是多家公司的执行董事。Biller博士获得了麻省理工学院的化学学士学位，加州理工学院和哥伦比亚大学的有机化学博士学位和国立卫生研究院博士后主攻天然产物的合成。
Scott Biller has served as a member of Remix's board of directors since July 2020. Since 2021, Dr. Biller has served as Executive Venture Partner at the venture capital fund GV. He previously served as the Chief Scientific Officer of Agios Pharmaceuticals from September 2010 to December 2019. Dr. Biller is also currently the sole proprietor of Biller Consulting, a consulting company serving the biopharmaceutical industry since 2020. Since 2020, Dr. Biller has served on the Board of Directors of Foghorn Therapeutics, Inc. and, from February 2021 to December 2025, served on the Board of Directors of Rome Therapeutics. In 2022, Dr. Biller joined the Board of Directors of OMass Therapeutics in Oxford, U.K and since 2023, he served as a board observer for Gate Biosciences. Dr. Biller earned a S.B. degree from the Massachusetts Institute of Technology, a Ph.D. from Caltech and was an NIH Postdoctoral Fellow at Columbia University in natural product synthesis. - Scott Biller于2010年9月加入Agios担任首席科学官，拥有超过25年的药物开发经验。最近，从2003年到2010年9月比勒博士是Novartis研究所的副总裁。在此之前，担任副总裁的位置。他是多家公司的执行董事。Biller博士获得了麻省理工学院的化学学士学位，加州理工学院和哥伦比亚大学的有机化学博士学位和国立卫生研究院博士后主攻天然产物的合成。
- Scott Biller has served as a member of Remix's board of directors since July 2020. Since 2021, Dr. Biller has served as Executive Venture Partner at the venture capital fund GV. He previously served as the Chief Scientific Officer of Agios Pharmaceuticals from September 2010 to December 2019. Dr. Biller is also currently the sole proprietor of Biller Consulting, a consulting company serving the biopharmaceutical industry since 2020. Since 2020, Dr. Biller has served on the Board of Directors of Foghorn Therapeutics, Inc. and, from February 2021 to December 2025, served on the Board of Directors of Rome Therapeutics. In 2022, Dr. Biller joined the Board of Directors of OMass Therapeutics in Oxford, U.K and since 2023, he served as a board observer for Gate Biosciences. Dr. Biller earned a S.B. degree from the Massachusetts Institute of Technology, a Ph.D. from Caltech and was an NIH Postdoctoral Fellow at Columbia University in natural product synthesis.
- Douglas G. Cole
-
Douglas G. Cole是一家上市生物技术公司Sana Biotechnology的董事会成员，也是多家私营公司的董事会成员。从2015年到2023年，Cole博士在Denali治疗和Sigilon治疗的董事会任职，这两家公司都是一家公共生命科学公司。Cole博士在宾夕法尼亚大学医学院获得医学博士学位，在Dartmouth学院获得英语学士学位。
Douglas G. Cole,serves on the board of directors of Sana Biotechnology, a public biotechnology company, and on the boards of directors of a number of private companies. From 2015 to 2023, Dr. Cole served on the boards of directors of Denali Therapeutics and Sigilon Therapeutics, each a public life sciences company. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College. - Douglas G. Cole是一家上市生物技术公司Sana Biotechnology的董事会成员，也是多家私营公司的董事会成员。从2015年到2023年，Cole博士在Denali治疗和Sigilon治疗的董事会任职，这两家公司都是一家公共生命科学公司。Cole博士在宾夕法尼亚大学医学院获得医学博士学位，在Dartmouth学院获得英语学士学位。
- Douglas G. Cole,serves on the board of directors of Sana Biotechnology, a public biotechnology company, and on the boards of directors of a number of private companies. From 2015 to 2023, Dr. Cole served on the boards of directors of Denali Therapeutics and Sigilon Therapeutics, each a public life sciences company. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College.
高管简历
中英对照 | 中文 | 英文- Adrian Gottschalk
Adrian Gottschalk自2017年5月起担任我们的总裁，首席执行官和董事会成员。在加入Foghorn之前，Gottschalk先生自2004年起在BiogenInc.工作，最近于2015年11月至2017年5月担任高级副总裁和神经变性治疗区负责人。在这个职位上，他负责阿尔茨海默氏症，帕金森氏症和肌萎缩侧索硬化症（ALS）药物的后期开发和商业化。Gottschalk先生拥有德州农工大学（Texas A&M University）的B.S.学位，麻省理工学院斯隆管理学院（Sloan School of Management at the Massachusetts Institute of Technology）的工商管理硕士学位和哈佛医学院/麻省理工学院联合健康科学与技术部门HST生物医学企业计划的硕士学位。
Adrian Gottschalk,worked at Biogen Inc. where he was most recently a Senior Vice President and Neurodegeneration Therapeutic Area Head from November 2015 to May 2017. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, or ALS. Mr. Gottschalk holds a B.S. from Texas A&M University, an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and an M.S. from the joint Harvard Medical School / Massachusetts Institute of Technology Division of Health Sciences & Technology (HST) Biomedical Enterprise Program.- Adrian Gottschalk自2017年5月起担任我们的总裁，首席执行官和董事会成员。在加入Foghorn之前，Gottschalk先生自2004年起在BiogenInc.工作，最近于2015年11月至2017年5月担任高级副总裁和神经变性治疗区负责人。在这个职位上，他负责阿尔茨海默氏症，帕金森氏症和肌萎缩侧索硬化症（ALS）药物的后期开发和商业化。Gottschalk先生拥有德州农工大学（Texas A&M University）的B.S.学位，麻省理工学院斯隆管理学院（Sloan School of Management at the Massachusetts Institute of Technology）的工商管理硕士学位和哈佛医学院/麻省理工学院联合健康科学与技术部门HST生物医学企业计划的硕士学位。
- Adrian Gottschalk,worked at Biogen Inc. where he was most recently a Senior Vice President and Neurodegeneration Therapeutic Area Head from November 2015 to May 2017. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, or ALS. Mr. Gottschalk holds a B.S. from Texas A&M University, an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and an M.S. from the joint Harvard Medical School / Massachusetts Institute of Technology Division of Health Sciences & Technology (HST) Biomedical Enterprise Program.
- Steven F. Bellon
Steven F.Bellon自2019年10月起担任我们的高级副总裁，药物发现，此前自2016年6月起担任药物发现Vice President。在加入Foghorn之前，Bellon博士从2008年9月开始担任Constellation Pharmaceuticals的高级董事兼执行董事。在Constellation Pharmaceuticals，Bellon博士建立了结构生物学集团和Bromodomain平台。Bellon博士在哈弗福德学院（Haverford College）获得学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得博士学位。
Steven F. Bellon,was Senior Director and Executive Director of Constellation Pharmaceuticals, starting in September 2008. At Constellation Pharmaceuticals, Dr. Bellon built the structural biology group and the bromodomain platform. Dr. Bellon has also held positions at Amgen and Vertex Pharmaceuticals and has more than 25 years of experience in drug discovery. Dr. Bellon received his B.S. from Haverford College and his Ph.D. from the Massachusetts Institute of Technology.- Steven F.Bellon自2019年10月起担任我们的高级副总裁，药物发现，此前自2016年6月起担任药物发现Vice President。在加入Foghorn之前，Bellon博士从2008年9月开始担任Constellation Pharmaceuticals的高级董事兼执行董事。在Constellation Pharmaceuticals，Bellon博士建立了结构生物学集团和Bromodomain平台。Bellon博士在哈弗福德学院（Haverford College）获得学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得博士学位。
- Steven F. Bellon,was Senior Director and Executive Director of Constellation Pharmaceuticals, starting in September 2008. At Constellation Pharmaceuticals, Dr. Bellon built the structural biology group and the bromodomain platform. Dr. Bellon has also held positions at Amgen and Vertex Pharmaceuticals and has more than 25 years of experience in drug discovery. Dr. Bellon received his B.S. from Haverford College and his Ph.D. from the Massachusetts Institute of Technology.
- Michael LaCascia
Michael Lacascia自2020年11月起担任我们的首席法务官。在加入Foghorn之前，拉卡西亚先生于2019年5月至2020年4月担任Q-State Biosciences，Inc.的高级副总裁and General Counsel，并于2020年4月至2020年10月担任首席法务官。从2014年1月到2015年10月，Lacascia先生是Vertex Pharmaceuticals Incorporated的副总裁，负责公司法律，后来从2015年10月到2019年2月成为Vertex的高级副总裁and General Counsel兼公司秘书。在Vertex任职之前，Lacascia先生是WilmerHale的股权合伙人，也是波士顿大学法学院的兼职讲师。Lacascia先生在哈佛大学获得学士学位，在波士顿大学法学院获得法学博士学位。
Michael LaCascia,served as Senior Vice President and General Counsel from May 2019 to April 2020 and Chief Legal Officer from April 2020 through October 2020 of Q-State BioSciences, Inc. From January 2014 through October 2015, Mr. LaCascia was a Vice President, Corporate Legal at Vertex Pharmaceuticals Incorporated and later became Vertex's Senior Vice President and General Counsel and Corporate Secretary from October 2015 through February 2019. Prior to his time at Vertex, Mr. LaCascia was an equity partner at WilmerHale and an adjunct lecturer at Boston University School of Law. Mr. LaCascia received his A.B. from Harvard College and his J.D. from Boston University School of Law.- Michael Lacascia自2020年11月起担任我们的首席法务官。在加入Foghorn之前，拉卡西亚先生于2019年5月至2020年4月担任Q-State Biosciences，Inc.的高级副总裁and General Counsel，并于2020年4月至2020年10月担任首席法务官。从2014年1月到2015年10月，Lacascia先生是Vertex Pharmaceuticals Incorporated的副总裁，负责公司法律，后来从2015年10月到2019年2月成为Vertex的高级副总裁and General Counsel兼公司秘书。在Vertex任职之前，Lacascia先生是WilmerHale的股权合伙人，也是波士顿大学法学院的兼职讲师。Lacascia先生在哈佛大学获得学士学位，在波士顿大学法学院获得法学博士学位。
- Michael LaCascia,served as Senior Vice President and General Counsel from May 2019 to April 2020 and Chief Legal Officer from April 2020 through October 2020 of Q-State BioSciences, Inc. From January 2014 through October 2015, Mr. LaCascia was a Vice President, Corporate Legal at Vertex Pharmaceuticals Incorporated and later became Vertex's Senior Vice President and General Counsel and Corporate Secretary from October 2015 through February 2019. Prior to his time at Vertex, Mr. LaCascia was an equity partner at WilmerHale and an adjunct lecturer at Boston University School of Law. Mr. LaCascia received his A.B. from Harvard College and his J.D. from Boston University School of Law.
- Carlos Costa
Carlos Costa曾在渤健担任过各种职责不断增加的职务，在多个领域和地区任职，包括西班牙、葡萄牙和意大利的人力资源业务合作伙伴，以及美国和新兴市场地区全球商业职能的人力资源主管。Costa先生最近在渤健担任的职务是欧洲、加拿大和国际合作伙伴市场的人力资源主管。在加入渤健之前，他在吉列和罗氏等公司担任了10年的HR业务合伙人，在那里他建立了团队、领导了转型并担任了业务的战略合伙人。Costa先生拥有西班牙UNED的法律学士学位，并在巴塞罗那的EADA获得了人力资源硕士学位。他还拥有马德里IE Instituto de Empresa的拼多多以及波士顿哈佛商学院的高管领导力项目。
Carlos Costa,held various roles of increasing responsibility at Biogen, in multiple areas and geographies ranging from human resources business partner for Spain, Portugal, and Italy, to HR lead for global commercial functions in the United States and the Emerging Markets region. In his most recent role at Biogen, Mr. Costa was the head of human resources for Europe, Canada, and International Partner Markets. Before joining Biogen, he spent 10 years serving as HR business partner in companies like Gillette and Roche, where he built teams, led transformations and served as strategic partner to the business. Mr. Costa holds a BS in law from UNED in Spain and received his human resources master's degree from EADA in Barcelona. He also holds a PDD from IE Instituto de Empresa, Madrid and the Executive Leadership Program at Harvard Business School, Boston.- Carlos Costa曾在渤健担任过各种职责不断增加的职务，在多个领域和地区任职，包括西班牙、葡萄牙和意大利的人力资源业务合作伙伴，以及美国和新兴市场地区全球商业职能的人力资源主管。Costa先生最近在渤健担任的职务是欧洲、加拿大和国际合作伙伴市场的人力资源主管。在加入渤健之前，他在吉列和罗氏等公司担任了10年的HR业务合伙人，在那里他建立了团队、领导了转型并担任了业务的战略合伙人。Costa先生拥有西班牙UNED的法律学士学位，并在巴塞罗那的EADA获得了人力资源硕士学位。他还拥有马德里IE Instituto de Empresa的拼多多以及波士顿哈佛商学院的高管领导力项目。
- Carlos Costa,held various roles of increasing responsibility at Biogen, in multiple areas and geographies ranging from human resources business partner for Spain, Portugal, and Italy, to HR lead for global commercial functions in the United States and the Emerging Markets region. In his most recent role at Biogen, Mr. Costa was the head of human resources for Europe, Canada, and International Partner Markets. Before joining Biogen, he spent 10 years serving as HR business partner in companies like Gillette and Roche, where he built teams, led transformations and served as strategic partner to the business. Mr. Costa holds a BS in law from UNED in Spain and received his human resources master's degree from EADA in Barcelona. He also holds a PDD from IE Instituto de Empresa, Madrid and the Executive Leadership Program at Harvard Business School, Boston.
- Alfonso Quintás Cardama
Alfonso Quint á s Cardama，2017年担任葛兰素史克PLC细胞与基因治疗部门的临床开发主管。在2014年至2016年期间，Quint á s-Cardama博士在诺华公司担任细胞与基因疗法全球临床负责人，并在2009年至2014年期间担任得克萨斯大学MD安德森癌症中心白血病系助理教授。Quint á s-Cardama博士在西班牙圣地亚哥大学孔波斯特拉医学院获得医学博士学位。他完成了阿尔伯特·爱因斯坦医学院医学系的实习和住院医师实习，并在德克萨斯大学医学博士安德森癌症中心完成了血液学和肿瘤学研究金和白血病研究金。
Alfonso Quintás Cardama,was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016, Dr. Quintás-Cardama served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás-Cardama received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine, and a hematology and oncology fellowship and a leukemia fellowship at the University of Texas, MD Anderson Cancer Center.- Alfonso Quint á s Cardama，2017年担任葛兰素史克PLC细胞与基因治疗部门的临床开发主管。在2014年至2016年期间，Quint á s-Cardama博士在诺华公司担任细胞与基因疗法全球临床负责人，并在2009年至2014年期间担任得克萨斯大学MD安德森癌症中心白血病系助理教授。Quint á s-Cardama博士在西班牙圣地亚哥大学孔波斯特拉医学院获得医学博士学位。他完成了阿尔伯特·爱因斯坦医学院医学系的实习和住院医师实习，并在德克萨斯大学医学博士安德森癌症中心完成了血液学和肿瘤学研究金和白血病研究金。
- Alfonso Quintás Cardama,was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016, Dr. Quintás-Cardama served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás-Cardama received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine, and a hematology and oncology fellowship and a leukemia fellowship at the University of Texas, MD Anderson Cancer Center.
- Anna Rivkin
Anna Rivkin，2021-2024年担任BMS免疫学、心血管和神经科学业务发展副总裁。Rivkin博士于2015年加入BMS从事业务发展，并担任过各种职责不断增加的角色。在加入BMS之前，Rivkin博士是默沙东的业务发展和许可总监，她的临床开发职业生涯就是在那里开始的。她拥有约翰霍普金斯大学的学士学位和凯斯西储大学医学院的博士学位。
Anna Rivkin,was the Vice President of Business Development for Immunology, Cardiovascular and Neuroscience at BMS from 2021-2024. Dr. Rivkin joined BMS in Business Development in 2015 and has held a variety of roles of increasing responsibility. Prior to her time at BMS, Dr. Rivkin was the Director of Business Development and Licensing at Merck having started her career there in Clinical Development. She holds a B.A. from Johns Hopkins University and Ph.D. from Case Western Reserve University School of Medicine.- Anna Rivkin，2021-2024年担任BMS免疫学、心血管和神经科学业务发展副总裁。Rivkin博士于2015年加入BMS从事业务发展，并担任过各种职责不断增加的角色。在加入BMS之前，Rivkin博士是默沙东的业务发展和许可总监，她的临床开发职业生涯就是在那里开始的。她拥有约翰霍普金斯大学的学士学位和凯斯西储大学医学院的博士学位。
- Anna Rivkin,was the Vice President of Business Development for Immunology, Cardiovascular and Neuroscience at BMS from 2021-2024. Dr. Rivkin joined BMS in Business Development in 2015 and has held a variety of roles of increasing responsibility. Prior to her time at BMS, Dr. Rivkin was the Director of Business Development and Licensing at Merck having started her career there in Clinical Development. She holds a B.A. from Johns Hopkins University and Ph.D. from Case Western Reserve University School of Medicine.
- Ryan D. Maynard
Ryan D. Maynard，2010年3月起，担任本公司的执行副总裁、首席财务官。他于2001年9月加入Rigel，担任企业财务总监；2001年10月，被任命为助理秘书。2006年6月，他成为财务副总裁、代理首席财务官；2007年1月，成为副总裁、首席财务官。加入Rigel之前，1999年11月至2001年4月，他担任Personify的企业财务总监、财务与会计总监，这是一个电子商务软件公司。1998年7月至1999年10月，他担任General Magic的财务总监；1994年7月至1998年6月，他在Siliconix担任过多个职务，最后的是高级财务经理。之前，他曾任职于Ernst & Young，期间成为注册会计师。他获得了Santa Clara University的商业会计学士学位。
Ryan D. Maynard,joined Board of Directors in February 2015. Mr. Maynard served as Chief Financial Officer of Cara Therapeutics, Inc., a publicly traded commercial-stage biopharmaceutical company, through April 2025. Previously he served as the Chief Financial Officer of LetsGetChecked, from October 2019 to early 2022. Mr. Maynard was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019. Until December 2017, he was the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Rigel's Vice President of Finance and Acting Chief Financial Officer and became its Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999, he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager. He previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce - Accounting from Santa Clara University.- Ryan D. Maynard，2010年3月起，担任本公司的执行副总裁、首席财务官。他于2001年9月加入Rigel，担任企业财务总监；2001年10月，被任命为助理秘书。2006年6月，他成为财务副总裁、代理首席财务官；2007年1月，成为副总裁、首席财务官。加入Rigel之前，1999年11月至2001年4月，他担任Personify的企业财务总监、财务与会计总监，这是一个电子商务软件公司。1998年7月至1999年10月，他担任General Magic的财务总监；1994年7月至1998年6月，他在Siliconix担任过多个职务，最后的是高级财务经理。之前，他曾任职于Ernst & Young，期间成为注册会计师。他获得了Santa Clara University的商业会计学士学位。
- Ryan D. Maynard,joined Board of Directors in February 2015. Mr. Maynard served as Chief Financial Officer of Cara Therapeutics, Inc., a publicly traded commercial-stage biopharmaceutical company, through April 2025. Previously he served as the Chief Financial Officer of LetsGetChecked, from October 2019 to early 2022. Mr. Maynard was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019. Until December 2017, he was the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Rigel's Vice President of Finance and Acting Chief Financial Officer and became its Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999, he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager. He previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce - Accounting from Santa Clara University.